Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma

Area of Science:

• Biomaterials Science
• Cancer Gene Therapy
• Nanotechnology

Background:

• Osteosarcoma is a prevalent bone cancer with poor survival rates for non-responsive or metastatic cases.
• Current treatments face challenges, necessitating novel therapeutic strategies.
• Gene therapy using Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) shows promise but is hindered by inefficient and toxic delivery vectors.

Purpose of the Study:

• To synthesize and evaluate a novel triazine-modified dendrimer (G5-DAT66) as a vector for TRAIL gene therapy in osteosarcoma.
• To assess the in vitro and in vivo transfection efficiency and therapeutic efficacy of G5-DAT66 for osteosarcoma treatment.

Main Methods:

• Synthesis of a triazine-modified dendrimer G5-DAT66.
• In vitro evaluation of transfection efficacy against commercial reagents (Lipofectamine 2000, SuperFect) in MG-63 osteosarcoma cells.
• Assessment of apoptosis induction in MG-63 cells and 3D cultures.
• In vivo studies in osteosarcoma-bearing mice to evaluate tumor transfection and growth inhibition.

Main Results:

• G5-DAT66 demonstrated superior transfection efficacy compared to Lipofectamine 2000 and SuperFect in MG-63 cells.
• The dendrimer effectively induced apoptosis in osteosarcoma cells in vitro.
• In vivo studies confirmed efficient TRAIL plasmid transfection in tumors and significant inhibition of tumor growth.

Conclusions:

• Triazine-modified dendrimer G5-DAT66 is a highly effective and low-toxic vector for TRAIL gene therapy.
• G5-DAT66 shows significant potential for the treatment of osteosarcoma.
• This nanocarrier offers a promising platform for advancing cancer gene therapy strategies.